Mineralys Seeks First-To-Market Edge In Uncontrolled Hypertension

10 Mar 2025

Battling AstraZeneca in the aldosterone inhibitor space, Mineralys reports Phase III data showing lorundrostat can significantly decrease uncontrolled/resistant blood pressure at six weeks.

Gloved hand holding a blood pressure meter, indicating high blood pressure — Mineralys shows its aldosterone inhibitor can benefit patients with uncontrolled hypertension • Source: Alamy

Mineralys reported data from a pair of clinical trials for lorundrostat (MLS-101) in uncontrolled or resistant hypertension on 10 March that it asserts could provide a new treatment option for about 10 million underserved high blood pressure patients in the US. The Radnor, PA-based firm said its selective aldosterone synthase inhibitor should be ready to file for approval at the US Food and Drug Administration with the latest study results.

Key Takeaways

Mineralys reports data from two studies showing that its aldosterone inhibitor can offer blood pressure-reducing benefit in uncontrolled or resistant cases.

Clinical-stage Mineralys is engaged in a tight, head-to-head battle with AstraZeneca to bring the first aldosterone inhibitor to market in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

12 Jun 2025

• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

11 Jun 2025

• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

11 Jun 2025

• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.